AN ENZYMATIC ASSAY TO MEASURE LONG-TERM ADHERENCE TO PRE EXPOSURE PROPHYLAXIS AND ANTIRETROVIRAL THERAPY

The disclosure addresses methods, compositions, and kits used to detect or quantify polymerase inhibitors in biological samples. The polymerase inhibitors can be therapeutic agents, or metabolites thereof, that have been administered to a subject as part of, for example, antiretroviral therapy (ART)...

Full description

Saved in:
Bibliographic Details
Main Authors Sevenler, Derin, Bender, Andrew, Zhang, Jane, Drain, Paul, Olanrewaju, Ayokunle, Posner, Jonathan, Sullivan, Benjamin, Sandlin, Rebecca
Format Patent
LanguageEnglish
Published 29.09.2022
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PHYSICS
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The disclosure addresses methods, compositions, and kits used to detect or quantify polymerase inhibitors in biological samples. The polymerase inhibitors can be therapeutic agents, or metabolites thereof, that have been administered to a subject as part of, for example, antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) to address potential infections by, e.g., retroviruses such as HIV and other viruses reliant on reverse transcription. These methods, compositions, and kits can be applied to monitor a subject's compliance with the indicated therapies and can inform potential adjustments to the therapies.
Bibliography:Application Number: US202017618323